Press Releases
Filter By Year
May
-
May 19, 2022
Gilead Reaches Number One Spot as Top Overall Philanthropic Funder of HIV-Related Programs, According to Funders Concerned About AIDS Report -
May 17, 2022
Gilead and Kite Oncology to Highlight Advances Supporting New Innovations in Cancer Care at the ASCO Annual Meeting -
May 16, 2022
FDA Lifts Clinical Hold on Investigational Lenacapavir for the Treatment and Prevention of HIV -
May 02, 2022
Gilead and Dragonfly Announce Strategic Research Collaboration to Develop Natural Killer Cell Engagers in Oncology and Inflammation
April
-
April 28, 2022
Gilead Sciences Announces First Quarter 2022 Financial Results -
April 26, 2022
Gilead Sciences to Present at Upcoming Investor Conferences -
April 25, 2022
Veklury® (Remdesivir) is First and Only Approved Treatment for Pediatric Patients Under 12 Years of Age with COVID-19 -
April 24, 2022
Several New Studies Presented at ECCMID 2022 Confirm Veklury® (Remdesivir) Activity in Treating COVID-19 -
April 19, 2022
Kite Receives U.S. FDA Approval of New State-of-the-Art CAR T-Cell Therapy Manufacturing Facility in Maryland -
April 14, 2022
Gilead Sciences to Release First Quarter 2022 Financial Results on Thursday, April 28, 2022 -
April 11, 2022
FDA Lifts Partial Clinical Hold on MDS and AML Magrolimab Studies -
April 01, 2022
Yescarta® Receives U.S. FDA Approval as First CAR T-cell Therapy for Initial Treatment of Relapsed or Refractory Large B-cell Lymphoma (LBCL)
March
-
March 28, 2022
Gilead Sciences Announces $24 Million in Grants to Help End the HIV Epidemic for Everyone, Everywhere -
March 07, 2022
Phase 3 TROPiCS-02 Study Met the Primary Endpoint of Progression-Free Survival in Late-Line HR+/HER2- Metastatic Breast Cancer -
March 01, 2022
Gilead Receives Complete Response Letter From U.S. FDA for Investigational Lenacapavir Due to Vial Compatibility Issues
February
-
February 16, 2022
New Clinical Data Support the Sustained Efficacy of Long-acting Lenacapavir, Gilead’s Investigational HIV-1 Capsid Inhibitor -
February 11, 2022
Phase 2/3 Interim Data Evaluating the Safety, Tolerability and Clinical Outcomes of Veklury® (Remdesivir) in Pediatric Patients With COVID-19 Presented at CROI 2022 -
February 11, 2022
Biktarvy® Demonstrates High Efficacy and Durable Viral Suppression at Five Years, in Treatment-Naïve Adults -
February 11, 2022
Veklury® (Remdesivir) Retains Antiviral Activity Against Omicron, Delta and Other Emergent SARS-CoV-2 Variants in Multiple In Vitro Studies -
February 08, 2022
Gilead to Present Latest Antiviral Research and Development Data at CROI 2022 Addressing Urgent Global Needs -
February 03, 2022
Gilead Sciences to Present at Upcoming Investor Conferences -
February 01, 2022
Gilead Sciences Announces 2.8 Percent Increase in First Quarter 2022 Dividend -
February 01, 2022
Gilead Sciences Announces Fourth Quarter and Full Year 2021 Financial Results
January
-
January 31, 2022
U.S. FDA Approves New Label Update for CAR T-Cell Therapy Yescarta® Showing Prophylactic Steroid Use Improves Management of Cytokine Release Syndrome -
January 25, 2022
Gilead Announces Partial Clinical Hold for Studies Evaluating Magrolimab in Combination With Azacitidine -
January 21, 2022
FDA Approves Veklury® (Remdesivir) for the Treatment of Non-Hospitalized Patients at High Risk for COVID-19 Disease Progression -
January 18, 2022
Gilead Sciences to Release Fourth Quarter & Full Year 2021 Financial Results on Tuesday, February 1, 2022 -
January 10, 2022
Gilead Announces Clinical Trial Collaborations With Merck to Evaluate Trodelvy® in Combination With KEYTRUDA® in First-Line Metastatic Non-Small Cell Lung Cancer
Filter By Year